Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;14(2):95-9.
doi: 10.1097/ACI.0000000000000031.

Engineered nanomaterial exposure and the risk of allergic disease

Affiliations
Review

Engineered nanomaterial exposure and the risk of allergic disease

Jonathan H Shannahan et al. Curr Opin Allergy Clin Immunol. 2014 Apr.

Abstract

Purpose of review: Although the production and use of engineered nanomaterials (ENMs) is rapidly increasing, we lack sufficient knowledge regarding their capacity to induce and/or promote allergic disease. As novel ENMs are being developed and used for biomedical applications, such as drug delivery, it will be critical to understand the relationship between physicochemical properties of ENMs and possible mechanisms of immunomodulation.

Recent findings: Cellular studies and a few animal studies have begun to examine the immunomodulatory effects of ENM exposure that may be predictive of developing allergic reactions. Specifically, the effects of direct ENM exposure on key immune cells recognized to facilitate allergic disease has been evaluated and will be discussed. However, few studies have reported specific physicochemical properties of ENMs that initiate allergic immune responses. Although limited, these descriptive studies point to the induction of cellular mechanisms that are well known to promote allergic disease.

Summary: The limited data currently available suggest that there is a potential risk for the development of allergic responses following exposure to ENMs. As more ENMs are developed for consumer products and nanomedicines, further study on their potential for adverse immune interactions will be necessary for safe implementation of these novel materials.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest for this work.

References

    1. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010 May;85(5):315–319. - PubMed
    1. Shima F, Uto T, Akagi T, et al. Size effect of amphiphilic poly(gamma-glutamic acid) nanoparticles on cellular uptake and maturation of dendritic cells in vivo. Acta Biomater. 2013 Nov;9(11):8894–8901. *Size of nanoparticles modifies dendritic cell uptake and activation demonstrating the importance of size as a physicochemical property which influences immune cell interactions.

    1. Toki S, Omary RA, Wilson K, et al. A comprehensive analysis of transfection-assisted delivery of iron oxide nanoparticles to dendritic cells. Nanomedicine. 2013 Jun 6; - PMC - PubMed
    1. Hirai T, Yoshikawa T, Nabeshi H, et al. Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection. Part Fibre Toxicol. 2012;9:3. - PMC - PubMed
    1. Park EJ, Bae E, Yi J, et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ Toxicol Pharmacol. 2010 Sep;30(2):162–168. - PubMed

Publication types